Hedgehog Signaling Modulators For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Hedgehog (Hh) signaling pathway is crucial for embryonic development and adult tissue homeostasis. While primarily known for its role in development and cancer, emerging research suggests Hh pathway modulation may have therapeutic potential in neurodegenerative diseases.
The Hh pathway consists of:
- Ligands: Sonic (SHH), Indian (IHH), Desert (DHH)
- Receptors: Patched (PTCH1), Smoothened (SMO)
- Transcription Factors: GLI1, GLI2, GLI3
- In absence of ligand, PTCH1 inhibits SMO
- Hh ligand binding releases SMO inhibition
- SMO activates GLI transcription factors
- GLI proteins regulate target genes
Hedgehog signaling may provide neuroprotection through:
- Neurogenesis: Promotion of neural stem cell proliferation
- Oligodendrogenesis: Support of oligodendrocyte precursor differentiation
- Synaptogenesis: Regulation of synaptic formation
- Axonal guidance: Developmental and regenerative processes
- Myelin maintenance: Oligodendrocyte function
- Anti-inflammatory effects: Modulation of glial activation
- Amyloid-beta effects on neural stem cells
- Impaired neurogenesis in hippocampus
- Potential for cognitive enhancement
- Research: PMID 19570512, PMID 21478264
- Dopaminergic neuron development and survival
- Potential for replacement therapy support
- α-synuclein modulation
- Research: PMID 22577003, PMID 24816217
- Motor neuron development
- Glial cell modulation
- Muscle innervation
- Research: PMID 25698356
- Oligodendrocyte precursor differentiation
- Remyelination promotion
- Clinical trials of SMO inhibitors in MS
- Research: PMID 21232923, PMID 25849474
- Neurogenesis promotion post-stroke
- Angiogenesis support
- Functional recovery enhancement
- Research: PMID 24154576
¶ Therapeutic Candidates
| Compound |
Mechanism |
Development Stage |
Company |
| Sonic Hedgehog (SHH) |
Native ligand |
Research |
Various |
| SAG |
SMO agonist |
Research tool |
Merck |
| Purmorphamine |
SMO agonist |
Research |
Various |
| Smoothened Agonist (SAG) |
SMO agonist |
Research |
Various |
- Vismodegib - FDA approved for basal cell carcinoma
- Sonidegib - FDA approved for basal cell carcinoma
- Not recommended for neurodegeneration
| Compound |
Activity |
Research Stage |
| GDC-0449 |
SMO inhibitor |
Cancer trials |
| IPI-926 |
SMO inhibitor |
Cancer trials |
Note: Hh inhibitors are used for cancers but may be detrimental in neurodegeneration.
- Timing: Pathway activation may be beneficial in early disease but harmful later
- Cancer risk: Chronic Hh activation linked to tumors
- BBB penetration: Many agents limited
- Specificity: SMO modulators have off-target effects
The field is still emerging. Most evidence is preclinical. Clinical trials have focused on:
- MS (SMO inhibitors for remyelination)
- Cancer (Hh inhibitors)
- Developmental disorders
- Temporal control of Hh pathway modulation
- Cell-type specific targeting
- Safe agonists for chronic use
- Combination with other approaches
- Biomarkers for pathway activation
The study of Hedgehog Signaling Modulators For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:19570512 - Hedgehog and Alzheimer's disease
- PMID:21478264 - Hh in neural stem cells
- PMID:22577003 - Hh and Parkinson's disease
- PMID:24816217 - Sonic hedgehog in PD models
- PMID:25698362 - Hedgehog in ALS
- PMID:21232923 - Hedgehog and oligodendrocytes
- PMID:25849474 - Hh in MS remyelination
- PMID:24154576 - Hh in stroke recovery